"Pharmaceutical headline king" loses more than a billion a year! The transformation of listed companies medical treatment is mired in a quagmire.

(2020/08/17) Pharmaceutical Technology Magazine: Continuous production progress, problems and challenges of solid preparations; The EU's first pre-order agreement for a new crown vaccine cost AstraZeneta... (Click on the title to get the original text) (Medicine 1st time) 400 million doses! The EU's first pre-order agreement for new crown vaccines cost AstraZeneta, and the European Commission (EC) has reached an agreement with AstraZeneta to buy 300 million doses of the vaccine on behalf of EU member states once the latter's potential vaccine for COVID-19, AZD1222, is proven to be safe and effective.
headline: The new deal doesn't make any money.
"Sai Bailan" National Discipline Inspection Inspection And Supervision Group stated: will thoroughly investigate medical corruption recently, the Central Commission for Discipline Inspection, the State Supervision Commission issued "anti-corruption three-person talk about the health care commission discipline inspection and supervision group: strengthen political supervision, strict investigation of violations of discipline and law" interview video and article.
In the interview, Yang Wei, deputy head of the discipline inspection and supervision group of the Central Commission for Discipline Inspection and Supervision of the National Health and Health Commission, pointed out that, as the accreding body of the State Supervision And Supervision Committee of the Central Commission for Discipline Inspection, the National Supervision and Inspection Committee of the Central Commission for Discipline Inspection and Supervision is based at the National Health and Health Commission, and is responsible for the comprehensive supervision of the National Health And Health Commission, the State Medical Security Administration, the State Administration of Traditional Chinese Medicine, the China Association for the Aging, the Chinese Red Cross Association and the Chinese Family Planning Association.
headlines: a nationwide wind-clearing signal has been sent out.
Yangzijiang winning product soared 180 times 13 heavyweights to prepare for the third round of national drug collection after the 2018 4-7 city pilot, 2019 alliance expansion, and then in 2020 the second Round of national collection, time after time after the actual grinding and adjustment, whether it is the selection of procurement varieties, or agreed procurement volume statistics, and even the adjustment of bidding rules are increasingly reasonable and mature, the third round will open on August 20, 56 varieties will usher in a price kill ... Headline bacteria: collection promotes normalization.
, U.S. Pharmaceutical Technology Magazine: Solid preparations continuous production progress, problems and challenges Recently, the FDA official website published a signed article by Director Stephen Hahn.
article said that in order to address supply chain pressures, the application of flexible manufacturing systems, in the context of the return of manufacturing to the United States, the FDA fully supports the application of advanced manufacturing technology in the industry, and continuous production is an important way.
: CM is a great opportunity to bring drugs to market.
stem cell therapy in some central neurological diseases progress and challenge stem cells according to the cell source and cell development stage, can be divided into embryonic stem cells (ESC) and adult stem cells (ASC).
can be divided into omnipotent stem cells (TSC), omnipotent stem cells (HSC) and specialized stem cells (USC) according to differentiation potential.
In 2006, Shinya Yamanka discovered induced omnicnicnicnic stem cells (iPSCs), which rule out ethical arguments that can be generated from patients' own cells, but still have many challenges to address before iPSCs-derived cells can be applied to cell therapy.
: The likelihood of stem cell applications is increasing.
"Look at the medical profession" a year to lose more than a billion! Listed companies transformation medical quagmire recently, by the real estate transformation of medical sector listed companies Yihua Health released the 2020 half-year results forecast, financial results show that from real estate to health care transformation in the past five years, Yihua Health's performance has been declining, in 2019 alone, a huge loss of more than a billion.
: How is the post-epidemic era transforming?